report fiscal adjust ep
consensu expect higher forecast better-than-
rate higher incom modest revenu out-performance contribut
upsid rel adjust ep forecast quarter
coo fiscal revenu increas year-over-year
organ million consensu expect
million estim million quarter coopervis
post better organ growth anticip versu
forecast includ improv result america pro forma
organ growth basi contrast coopersurg result weak
organ year-over-year declin genet test product
within fertil segment reflect aggress price competitor
chosen follow off-set favor perform
offic surgic product organ remaind
fertil busi organ
pro
suggest gray market purchas compani contact lens
reduc coopervis america organ growth percentag
point recent quarter correspond benefit emea sale
coopersurg reflect expect two
difficult quarter genet test addit compani rais
adjust ep guidanc result
addit benefit currenc movement benefit
postpon medic devic tax lower tax rate
assumpt modest upsid rel prior guidanc paragard
acquisit headwind interest expens given compani
revis expect three rate increas year
announc al white cfo chief strategi offic succeed
bob weiss compani presid ceo effect may
expect seamless transit view announc favor
reduc adjust ep estim
total debt total asset
sale declin coo genet test segment disappoint
view situat manag busi repres roughli
coo total sale importantli encourag strong start
year coopervis think guidanc segment look conserv
given eas comp america region upcom quarter fear
regard coopervis america outlook lessen see opportun
modest multipl expans maintain buy rate price
target
import pleas read disclosur disclaim page report
report fiscal adjust ep consensu expect higher
forecast better-than-expect adjust oper margin lower-than-anticip adjust tax rate
higher incom modest revenu out-performance contribut upsid rel adjust ep
forecast quarter
coo fiscal revenu increas year-over-year million consensu
expect million estim million quarter compani organ growth
modestli forecast larger anticip revenu benefit currenc chang
drive upsid rel revenu forecast divis standpoint stronger-than-expect organ
cooper compani incfisc adjust ep analysisnorthcoast research thousand except percentag per share gross gross sg sg oper oper net interest incom interest incom incom incom incom tax adjust net adjust net net net wghd com share ep ep revenu growth adjust ep growth analysi revenu compani report northcoast research estim factset growth coopervis off-set much weaker perform coopersurg
fiscal coopervis achiev organ growth approxim estim
note coopervis pro forma organ growth includ million revenu procornea
paragon acquisit combin basi roughli year-over-year geograph
standpoint pro forma organ growth coopervis asia pacif emea busi remain strong
pro forma organ growth basi respect compani also post better result
america pro forma organ growth basi notabl also suggest gray market purchas
compani contact lens reduc coopervis america organ growth percentag point
recent quarter correspond benefit emea sale think help bridg gap
coopervis weak report america result recent quarter compani favor feedback
regard end-us demand trend product
product perspect coopervis continu led robust growth sale daili silicon hydrogel
lens clariti myday increas year-over-year constant currenc basi combin
biofin avaira busi increas year-over-year regard world-wide contact len market
coopervis calendar constant currenc growth similar overal market second
straight quarter said expect coopervis resum gain market share upcom quarter
year-over-year comparison america begin eas
coopersurg achiev neg organ growth fiscal well estim
quarter year-over-year declin genet test product within fertil segment reflect
aggress price competitor chose follow off-set favor perform
offic surgic product organ remaind fertil busi organ
addit fiscal revenu coo paragard acquisit million year-
over-year expect due time larg price increas product prior owner teva
pull sale coo fiscal fall said compani continu expect strong result mid-
to-high single-digit organ growth busi remaind fiscal year
coopervis inc organ growth analysissourc compani report northcoast research exclud aim csi fiscal organ growth analysisnorthcoast research csi organ growthtot coopersurg surgic genet fertil report northcoast research estim
coo fiscal adjust oper margin increas bp year-over-year well
estim quarter strong adjust gross bp year-over-year account
upsid versu adjust oper margin forecast busi standpoint currenc chang
product mix manufactur effici contribut roughli bp improv
coopervis adjust gross margin quarter inclus high-margin paragard busi
account bp year-over-year improv coopersurg adjust gross margin
maintain pro forma organ growth outlook coopervis lower
outlook coopersurg pro forma organ growth reflect expect two
difficult quarter genet test addit compani rais adjust ep guidanc
note revis adjust ep guidanc includ addit benefit
currenc movement benefit postpon medic devic tax lower tax rate
assumpt modest upsid rel prior guidanc paragard acquisit headwind
interest expens given compani revis expect three rate increas year total
reduc adjust ep estim reflect higher interest expens assumpt
addit releas fiscal result also announc al white cfo chief strategi offic
succeed bob weiss compani presid ceo effect may expect seamless
transit view announc favor
overal sale declin coo genet test segment disappoint view situat
manag busi repres roughli coo total sale importantli
encourag strong start year coopervis think guidanc segment look
conserv given eas comp america region upcom quarter fear regard coopervis
america outlook lessen see opportun modest multipl expans maintain buy rate
price target
cooper compani inc annual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg amort oper oper net interest interest incom incom incom incom tax minor net incom extra net margin extra extra net net wghd com share ep ep revenu growth adjust ep growth began exclud amort intang adjust ep follow sauflon acquisitionsourc compani report northcoast research estim disclosur
